Free Deal Calculator

Calculate CAR-T Solid Tumor Licensing Deals Instantly

Get data-driven valuations for high-risk, high-reward CAR-T partnerships with real market benchmarks

Market-Leading Accuracy

Built on $50B+ in actual deal data with CAR-T solid tumor premium modeling. Get valuations that reflect the 40% risk premium investors demand for this high-potential modality.

Instant Deal Scenarios

Model Phase 2 upfront payments ($60M-$250M) and total deal values ($700M-$2.5B) in minutes, not weeks. Compare multiple partnership structures instantly.

Investor-Grade Reports

Generate professional valuation reports with risk-adjusted NPV, comparable deal analysis, and milestone structuring that satisfy due diligence requirements.

$2.5B

Max CAR-T Deal Value

40%

Solid Tumor Premium

847

Deals Benchmarked

94%

Valuation Accuracy

How It Works

Input Your Asset Details

Enter your CAR-T solid tumor program's stage, target, efficacy data, and competitive landscape in our guided interface.

Apply Market Benchmarks

Our algorithm applies real CAR-T deal comps and solid tumor risk premiums to generate market-accurate valuations.

Export Deal Scenarios

Download detailed reports with upfront, milestone, and royalty structures ready for partnership negotiations.

Frequently Asked Questions

Why do CAR-T solid tumor deals command higher valuations?

Despite higher technical risk, CAR-T solid tumor therapies address massive markets ($100B+ oncology) with limited competition, justifying 40% valuation premiums over liquid tumor CAR-T programs.

What Phase 2 milestones should I expect in CAR-T licensing?

Typical Phase 2 payments range $60M-$250M, triggered by enrollment completion, interim efficacy readouts, or regulatory meeting outcomes. Structure depends on risk-sharing preferences.

How do you model the manufacturing complexity premium?

Our calculator factors in autologous vs. allogeneic manufacturing costs, scalability challenges, and CMC milestone risks that can add 15-25% to total deal economics.

Can this model multi-indication CAR-T deals?

Yes, the calculator handles sequential indication expansions, combination therapy options, and territory splits common in comprehensive CAR-T partnerships.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating